Erratum for "Expression of hypoxia-inducible factor 1α, hypoxia-inducible factor 2α, and von Hippel-Lindau protein in epithelial ovarian neoplasms and allelic loss of von Hippel-Lindau gene: nuclear expression of hypoxia-inducible factor 1α is an independent prognostic factor in ovarian carcinoma" [Hum Pathol 38 (2007) 1310-1320] (DOI:10.1016/j.humpath.2007.02.010);Expression of hypoxia-inducible factor 1α, hypoxia-inducible factor 2α, and von Hippel-Lindau protein in epithelial ovarian neoplasms and allelic loss of von Hippel-Lindau gene: nuclear expression of hypoxia-inducible factor 1α is an independent prognostic factor in ovarian carcinoma

Human Pathology

Volumn 38, Issue 9, 2007, Pages 1310-1320

  Osada, Ryosuke ^a   Horiuchi, Akiko ^a   Kikuchi, Norihiko ^a   Yoshida, Junko ^a   Hayashi, Akiko ^a   Ota, Masao ^a   Katsuyama, Yoshihiko ^b   Mellilo, Giovanni ^c   Konishi, Ikuo ^a  

^a SHINSHU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b SHINSHU UNIVERSITY HOSPITAL   (Japan)

^c SAIC FREDERICK INC   (United States)

Author keywords

HIF 1 ; HIF 2 ; Ovarian carcinoma; Prognosis; VHL

Indexed keywords

HYPOXIA INDUCIBLE FACTOR 1ALPHA; HYPOXIA INDUCIBLE FACTOR 2ALPHA; VASCULOTROPIN; VON HIPPEL LINDAU PROTEIN;

ARTICLE; CANCER GROWTH; CANCER STAGING; CARCINOGENESIS; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOPLASM; FEMALE; GENE LOCUS; HETEROZYGOSITY LOSS; HISTOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LOG RANK TEST; MULTIVARIATE ANALYSIS; OVARY CARCINOMA; OVARY TUMOR; PROGNOSIS; PROTEIN EXPRESSION;

EID: 34547838192     PISSN: 00468177     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.humpath.2007.11.010     Document Type: Erratum

References (38)

1. Murdoch W.J. Ovarian surface epithelium, ovulation and carcinogenesis. Biol Rev Camb Philos Soc 71 (1996) 529-543
2. Mutch D.G., and Williams S. Biology of epithelial ovarian cancer. Clin Obstet Gynecol 37 (1994) 406-422
3. Harris A.L. Hypoxia-a key regulatory factor in tumour growth. Nat Rev Cancer 2 (2002) 38-47
4. Hockel M., and Vaupel P. Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. J Natl Cancer Inst 93 (2001) 266-276
5. Imai T., Horiuchi A., Wang C., et al. Hypoxia attenuates the expression of E-cadherin via up-regulation of SNAIL in ovarian carcinoma cells. Am J Pathol 163 (2003) 1437-1447
6. 2 homeostasis by hypoxia-inducible factor 1. Annu Rev Cell Dev Biol 15 (1999) 551-578
7. Semenza G.L. Targeting HIF-1 for cancer therapy. Nat Rev Cancer 3 (2003) 721-732
8. Jain S., Maltepe E., Lu M.M., Simon C., and Bradfield C.A. Expression of ARNT, ARNT2, HIF1 alpha, HIF2 alpha and Ah receptor mRNAs in the developing mouse. Mech Dev 73 (1998) 117-123
9. Covello K.L., Kehler J., Yu H., et al. HIF-2alpha regulates Oct-4: effects of hypoxia on stem cell function, embryonic development, and tumor growth. Genes Dev 20 (2006) 557-570
10. Sowter H.M., Raval R.R., Moore J.W., Ratcliffe P.J., and Harris A.L. Predominant role of hypoxia-inducible transcription factor (HIF)-1alpha versus HIF-2alpha in regulation of the transcriptional response to hypoxia. Cancer Res 63 (2003) 6130-6134
11. Hu C.J., Iyer S., Sataur A., Covello K.L., Chodosh L.A., and Simon M.C. Differential regulation of the transcriptional activities of hypoxia-inducible factor 1 alpha (HIF-1alpha) and HIF-2alpha in stem cells. Mol Cell Biol 26 (2006) 3514-3526
12. Warnecke C., Zaborowska Z., Kurreck J., et al. Differentiating the functional role of hypoxia-inducible factor (HIF)-1alpha and HIF-2alpha (EPAS-1) by the use of RNA interference: erythropoietin is a HIF-2alpha target gene in Hep3B and Kelly cells. FASEB J 18 (2004) 1462-1464
13. Scully RE, Young RH, Clement PB. Tumors of the ovary and maldeveloped gonads, fallopian tube, and broad ligament. Atlas of Tumor Pathology, 3rd series 1998; Fascicle 23. Washington (DC): Armed Forces Institute of Pathology. pp 51-168.
14. Silverberg S.G. Histopathologic grading of ovarian carcinoma: a review and proposal. Int J Gynecol Pathol 19 (2000) 7-15
15. Yoshimura H., Dhar D.K., Kohno H., et al. Prognostic impact of hypoxia-inducible factors 1alpha and 2alpha in colorectal cancer patients: correlation with tumor angiogenesis and cyclooxygenase-2 expression. Clin Cancer Res 10 (2004) 8554-8560
16. Birner P., Schindl M., Obermair A., Breitenecker G., and Oberhuber G. Expression of hypoxia-inducible factor 1alpha in epithelial ovarian tumors: its impact on prognosis and on response to chemotherapy. Clin Cancer Res 7 (2001) 1661-1668
17. Talks K.L., Turley H., Gatter K.C., et al. The expression and distribution of the hypoxia-inducible factors HIF-1alpha and HIF-2alpha in normal human tissues, cancers, and tumor-associated macrophages. Am J Pathol 157 (2000) 411-421
18. Weidner N., Semple J.P., Welch W.R., et al. Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma. N Engl J Med 324 (1991) 1-8
19. Osada R., Horiuchi A., Kikuchi N., et al. Expression of semaphorins, VEGF and their common receptor neuropilins, and allelic loss of SEMA locus in epithelial ovarian neoplasms: increased VEGF/SEMA ratio is a poor prognostic factor in ovarian carcinomas. Hum Pathol 37 (2006) 1414-1425
20. Wang C., Horiuchi A., Imai T., et al. Expression of BRCA1 protein in benign, borderline, and malignant epithelial ovarian neoplasms and its relationship to methylation and allelic loss of the BRCA1 gene. J Pathol 202 (2004) 215-223
21. Igarashi H., Esumi M., Ishida H., and Okada K. Vascular endothelial growth factor overexpression is correlated with von Hippel-Lindau tumor suppressor gene inactivation in patients with sporadic renal cell carcinoma. Cancer 95 (2002) 47-53
22. Hunt J.L., Yim J.H., Tometsko M., et al. Loss of heterozygosity of the VHL gene identifies malignancy and predicts death in follicular thyroid tumors. Surgery 134 (2003) 1043-1047
23. Sivridis E., Giatromanolaki A., Gatter K.C., Harris A.L., Koukourakis M.I., and Tumor and Angiogenesis Research Group. Association of hypoxia-inducible factors 1alpha and 2alpha with activated angiogenic pathways and prognosis in patients with endometrial carcinoma. Cancer 95 (2002) 1055-1063
24. Jones A., Fujiyama C., Blanche C., et al. Relation of vascular endothelial growth factor production to expression and regulation of hypoxia-inducible factor-1 alpha and hypoxia-inducible factor-2 alpha in human bladder tumors and cell lines. Clin Cancer Res 7 (2001) 1263-1272
25. Giatromanolaki A., Koukourakis M.I., Sivridis E., et al. Relation of hypoxia inducible factor 1 alpha and 2 alpha in operable non-small cell lung cancer to angiogenic/molecular profile of tumours and survival. Br J Cancer 85 (2001) 881-890
26. Ratcliffe P.J., O'Rourke J.F., Maxwell P.H., and Pugh C.W. Oxygen sensing, hypoxia-inducible factor-1 and the regulation of mammalian gene expression. J Exp Biol 201 (1998) 1153-1162
27. Beasley N.J., Leek R., Alam M., et al. Hypoxia-inducible factors HIF-1alpha and HIF-2alpha in head and neck cancer: relationship to tumor biology and treatment outcome in surgically resected patients. Cancer Res 62 (2002) 2493-2497
28. Koukourakis M.I., Bentzen S.M., Giatromanolaki A., et al. Endogenous markers of two separate hypoxia response pathways (hypoxia inducible factor 2 alpha and carbonic anhydrase 9) are associated with radiotherapy failure in head and neck cancer patients recruited in the CHART randomized trial. J Clin Oncol 24 (2006) 727-735
29. Generali D., Berruti A., Brizzi M.P., et al. Hypoxia-inducible factor-1alpha expression predicts a poor response to primary chemoendocrine therapy and disease-free survival in primary human breast cancer. Clin Cancer Res 12 (2006) 4562-4568
30. Burke B., Tang N., Corke K.P., et al. Expression of HIF-1alpha by human macrophages: implications for the use of macrophages in hypoxia-regulated cancer gene therapy. J Pathol 196 (2002) 204-212
31. Nilsson H., Jogi A., Beckman S., Harris A.L., Poellinger L., and Pahlman S. HIF-2alpha expression in human fetal paraganglia and neuroblastoma: relation to sympathetic differentiation, glucose deficiency, and hypoxia. Exp Cell Res 303 (2005) 447-456
32. Hon W.C., Wilson M.I., Harlos K., et al. Structural basis for the recognition of hydroxyproline in HIF-1 alpha by pVHL. Nature 417 (2002) 975-978
33. Min J.H., Yang H., Ivan M., Gertler F., Kaelin Jr. W.G., and Pavletich N.P. Structure of an HIF-1alpha-pVHL complex: hydroxyproline recognition in signaling. Science 296 (2002) 1886-1889
34. Horiuchi A., Imai T., Shimizu M., et al. Hypoxia-induced changes in the expression of VEGF, HIF-1 alpha and cell cycle-related molecules in ovarian cancer cells. Anticancer Res 22 (2002) 2697-2702
35. Boocock C.A., Charnock-Jones D.S., Sharkey A.M., et al. Expression of vascular endothelial growth factor and its receptors flt and KDR in ovarian carcinoma. J Natl Cancer Inst 87 (1995) 506-516
36. Yamamoto S., Konishi I., Mandai M., et al. Expression of vascular endothelial growth factor (VEGF) in epithelial ovarian neoplasms: correlation with clinicopathology and patient survival, and analysis of serum VEGF levels. Br J Cancer 76 (1997) 1221-1227
37. Bamberger E.S., and Perrett C.W. Angiogenesis in epithelial ovarian cancer. Mol Pathol 55 (2002) 348-359
38. Melillo G. Inhibiting hypoxia-inducible factor 1 for cancer therapy. Mol Cancer Res 4 (2006) 601-605